Kelly KR - Search Results

1

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS. Swords RT, et al. Among authors: kelly kr. Blood. 2010 May 6;115(18):3796-800. doi: 10.1182/blood-2009-11-254862. Epub 2010 Mar 4. Blood. 2010. PMID: 20203261 Free article.

2

Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.

Kelly K, Swords R, Kilcoyne A, Sankhala K, Mahalingam D, Padmanabhan S, Giles F. Kelly K, et al. Leuk Lymphoma. 2009 Feb;50(2):297-9. doi: 10.1080/10428190802607541. Leuk Lymphoma. 2009. PMID: 19160124 No abstract available.

3

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.

Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Kelly K, et al. Target Oncol. 2009 Apr;4(2):99-105. doi: 10.1007/s11523-009-0110-4. Epub 2009 Apr 21. Target Oncol. 2009. PMID: 19381453 Review.

4

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.

Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. Sankhala K, et al. Target Oncol. 2009 Apr;4(2):135-42. doi: 10.1007/s11523-009-0107-z. Epub 2009 Apr 21. Target Oncol. 2009. PMID: 19381454 Review.

5

Emerging drugs in the treatment of pancreatic cancer.

Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Mahalingam D, et al. Among authors: kelly kr. Expert Opin Emerg Drugs. 2009 Jun;14(2):311-28. doi: 10.1517/14728210902972502. Expert Opin Emerg Drugs. 2009. PMID: 19466902 Review.

6

Reovirus-based therapy for cancer.

Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M. Kelly K, et al. Expert Opin Biol Ther. 2009 Jul;9(7):817-30. doi: 10.1517/14712590903002039. Expert Opin Biol Ther. 2009. PMID: 19527106 Review.

7

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.

Carew JS, Medina EC, Esquivel JA 2nd, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST. Carew JS, et al. J Cell Mol Med. 2010 Oct;14(10):2448-59. doi: 10.1111/j.1582-4934.2009.00832.x. J Cell Mol Med. 2010. PMID: 19583815 Free PMC article.

8

Cdc7 kinase - a new target for drug development.

Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F. Swords R, et al. Eur J Cancer. 2010 Jan;46(1):33-40. doi: 10.1016/j.ejca.2009.09.020. Eur J Cancer. 2010. PMID: 19815406 Review.

9

Targeting sarcomas: novel biological agents and future perspectives.

Mahalingam D, Mita A, Sankhala K, Swords R, Kelly K, Giles F, Mita MM. Mahalingam D, et al. Curr Drug Targets. 2009 Oct;10(10):937-49. doi: 10.2174/138945009789577990. Curr Drug Targets. 2009. PMID: 19860642 Review.

10

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST. Mahalingam D, et al. Among authors: kelly kr. Clin Cancer Res. 2010 Jan 1;16(1):141-53. doi: 10.1158/1078-0432.CCR-09-1385. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028765

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

195 results

Search Page

Filters